American Bio Medica Corporation

Equities

ABMC

US0246001087

Medical Equipment, Supplies & Distribution

Market Closed - OTC Markets Other stock markets 15:08:48 28/05/2024 BST			5-day change	1st Jan Change
0.0001 ^USD	-.--%		-.--%	-.--%

2023	American Bio Medica Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
2023	American Bio Medica Corporation Auditor Raises 'Going Concern' Doubt	CI

American Bio Medica Corporation Reports Earnings Results for the Full Year Ended December 31, 2019

June 26, 2020 at 10:21 pm

American Bio Medica Corporation announced earnings results for the full year ended December 31, 2019. For the full year, the company announced sales was USD 3.655 million compared to USD 3.872 million a year ago. Operating loss was USD 593,000 compared to USD 762,000 a year ago. Net loss was USD 681,000 compared to USD 1.028 million a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.03 a year ago.

Latest news about American Bio Medica Corporation

American Bio Medica Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	12/06/23	CI
American Bio Medica Corporation Auditor Raises 'Going Concern' Doubt	20/03/23	CI
American Bio Medica Corporation Announces Termination of Melissa A. Waterhouse as Principal Financial Officer	01/03/23	CI
American Bio Medica Corporation Announces Termination of Melissa A. Waterhouse as Chief Executive Officer	01/03/23	CI
Healgen Scientific LLC completed the acquisition of substantially all of the operating assets of American Bio Medica Corporation.	27/02/23	CI
Healgen Scientific LLC agreed to acquire substantially all of the operating assets of American Bio Medica Corporation for $3 million.	20/12/22	CI
American Bio Medica Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	16/11/22	CI
American Bio Medica Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15/08/22	CI
American Bio Medica Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	16/05/22	CI
American Bio Medica Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	15/04/22	CI
American Bio Medica Corporation Auditor Raises 'Going Concern' Doubt	14/04/22	CI
American Bio Medica Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	18/11/21	CI
American Bio Medica Corporation announced that it has received $0.1 million in funding	17/10/21	CI
Declaration of Voting Results by American Bio	29/06/21	CI
John J. Moroney Engages in Discussions with American Bio Medica	01/06/21	CI
American Bio Medica Corporation Reports Earnings Results for the First Quarter Ended March 31, 2021	20/05/21	CI
Earnings Flash (ABMC) AMERICAN BIO MEDICA CORPORATION Reports Q1 Loss $-0.01	20/05/21	MT
American Bio Medica Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2020	15/04/21	CI
American Bio Medica Corporation Announces Resignation of Chaim Davis from the Board of Directors	11/02/21	CI
American Bio Medica Corporation announced that it expects to receive $0.125 million in funding from Lincoln Park Capital, LLC	09/12/20	CI
American Bio Medica Corporation Reports Earnings Results for the Third Quarter Ended September 30, 2020	16/11/20	CI
American Bio Medica : Earnings Flash (ABMC) AMERICAN BIO MEDICA CORPORATION Posts Q3 EPS $-0.01	16/11/20	MT
American Bio Medica Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2020	15/09/20	CI
American Bio Medica Corporation Reports Earnings Results for the First Quarter Ended March 31, 2020	31/07/20	CI
American Bio Medica Corporation Reports Earnings Results for the Full Year Ended December 31, 2019	26/06/20	CI

Chart American Bio Medica Corporation

Duration

Period

More charts

Company Profile

American Bio Medica Corporation is engaged in the manufacturing and distribution of lateral flow immunoassay tests, primarily for the immediate detection of drugs in urine and oral fluid. The Company also distributes a number of other products related to the immediate detection of drugs and alcohol. It manufactures a number of products that detect the presence or absence of drugs in urine. It manufactures the various urine drug testing product lines, including The Rapid Drug Screen (RDS), RDS InCup, Rapid TOX, Rapid TOX Cup and Private Label Products. RDS is a patented rapid drug test that detects the presence or absence of 2-10 drugs simultaneously in a single urine specimen. RDS InCup is a drug-testing cup that detects the presence or absence of 1-12 drugs in a urine specimen. Its OralStat is a drug test for the detection of drugs in oral fluids. Its Respiratory Syncytial Virus (RSV) test does detect RSV in both children under the age of six, as well as adults over the age of 60.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Income Statement Evolution

More financial data

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
AMERICAN BIO MEDICA CORPORATION	-.--%	4.81K
BIOMÉRIEUX	-4.52%	12.39B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-3.76%	8.43B
DIASORIN S.P.A.	+6.71%	5.77B
LANTHEUS HOLDINGS, INC.	+31.48%	5.76B
AUTOBIO DIAGNOSTICS CO., LTD.	-10.28%	4.1B
ANDON HEALTH CO., LTD.	+10.72%	2.66B
10X GENOMICS, INC.	-61.53%	2.66B
VITROLIFE AB	-8.27%	2.39B
MYRIAD GENETICS, INC.	+16.56%	2.02B

Diagnostic & Testing Substances